GoodRx (NASDAQ:GDRX) Major Shareholder Francisco Partners Iv, L.P. Sells 143,594 Shares of Stock

Key Points

• Francisco Partners sold 143,594 GoodRx shares at an average price of $3.46, reducing its position by 16.89% to 706,649 shares. The shareholder also sold millions of additional shares in transactions from August 19–26.
• GoodRx shares recently traded at $3.65, with the stock up from its 50-day and 200-day moving averages but still below its 12-month high of $5.81. The company reported quarterly revenue of $200.41 million and adjusted earnings of $0.08 per share, while revenue declined 1.3% year over year.
• Analysts have an overall “Hold” rating on GoodRx, with an average price target of $4.23; several firms raised targets to $5.00, while institutional investors own 63.77% of the company.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) major shareholder Francisco Partners Iv, L.P. sold 143,594 shares of the stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $3.46, for a total transaction of $496,835.24. Following the completion of the sale, the insider directly owned 706,649 shares in the company, valued at approximately $2,445,005.54. This trade represents a 16.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Francisco Partners Iv, L.P. also recently made the following trade(s):

• On Wednesday, August 26th, Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock. The shares were sold at an average price of $3.50, for a total transaction of $4,536,619.50.
• On Tuesday, August 25th, Francisco Partners Iv, L.P. sold 127,273 shares of GoodRx stock. The stock was sold at an average price of $3.44, for a total transaction of $437,819.12.
• On Friday, August 21st, Francisco Partners Iv, L.P. sold 274,717 shares of GoodRx stock. The stock was sold at an average price of $3.50, for a total transaction of $961,509.50.
• On Thursday, August 20th, Francisco Partners Iv, L.P. sold 447,259 shares of GoodRx stock. The shares were sold at an average price of $3.52, for a total transaction of $1,574,351.68.
• On Wednesday, August 19th, Francisco Partners Iv, L.P. sold 471,975 shares of GoodRx stock. The shares were sold at an average price of $3.53, for a total value of $1,666,071.75.

GoodRx Stock Performance

Shares of GDRX traded up $0.18 during mid-day trading on Wednesday, reaching $3.65. 3,534,816 shares of the company's stock traded hands, compared to its average volume of 1,909,305. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.38 and a current ratio of 1.38. The business's 50-day moving average price is $3.18 and its 200-day moving average price is $2.66. The stock has a market capitalization of $1.25 billion, a P/E ratio of 91.27, a price-to-earnings-growth ratio of 1.73 and a beta of 1.60. GoodRx Holdings, Inc. has a 12 month low of $1.77 and a 12 month high of $5.81.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.08. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The business had revenue of $200.41 million during the quarter, compared to analyst estimates of $193.23 million. During the same period in the prior year, the company posted $0.09 EPS. The business's revenue for the quarter was down 1.3% compared to the same quarter last year. Equities analysts predict that GoodRx Holdings, Inc. will post 0.16 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Citigroup increased their price target on GoodRx from $4.00 to $5.00 and gave the stock a "buy" rating in a research note on Tuesday, August 11th. Wells Fargo & Company lifted their price objective on shares of GoodRx from $3.50 to $5.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Leerink Partners set a $5.00 price objective on shares of GoodRx in a report on Thursday, August 6th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $4.00 target price on shares of GoodRx in a research report on Friday, August 7th. Finally, Weiss Ratings raised shares of GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, August 7th. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $4.23.

Hedge Funds Weigh In On GoodRx

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of GoodRx by 7.3% in the 3rd quarter. Vanguard Group Inc. now owns 9,207,340 shares of the company's stock worth $38,947,000 after purchasing an additional 624,182 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in GoodRx by 4.0% during the second quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company's stock valued at $24,001,000 after purchasing an additional 184,734 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in GoodRx by 1.5% during the first quarter. Renaissance Technologies LLC now owns 3,259,738 shares of the company's stock worth $6,389,000 after buying an additional 48,800 shares in the last quarter. LSV Asset Management boosted its holdings in GoodRx by 20.0% during the fourth quarter. LSV Asset Management now owns 2,825,900 shares of the company's stock worth $7,658,000 after buying an additional 471,319 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in GoodRx by 6.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,650,452 shares of the company's stock worth $7,183,000 after buying an additional 152,934 shares during the last quarter. Institutional investors own 63.77% of the company's stock.

GoodRx Company Profile

GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source